Galectin Therapeutics (GALT) Total Non-Current Liabilities (2010 - 2026)

Galectin Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $143.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 17.56% year-over-year to $143.0 million in Q1 2026; TTM through Mar 2026 was $143.0 million, a 17.56% increase from a year earlier, with the FY2025 full-year figure at $141.8 million, up 17.68% from the prior year.
• Total Non-Current Liabilities improved to $143.0 million in Q1 2026 per GALT's latest filing, from $141.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $143.0 million in Q1 2026 and bottomed at $39.4 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $96.9 million (2024), against an average of $93.5 million.
• Across the five-year window, Total Non-Current Liabilities jumped 745.31% in 2022 and increased 13.47% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $53.3 million in 2022, then jumped by 65.23% to $88.0 million in 2023, then soared by 36.88% to $120.5 million in 2024, then grew by 17.68% to $141.8 million in 2025, then grew by 0.88% to $143.0 million in 2026.
• Per Business Quant, the three latest GALT Total Non-Current Liabilities figures stand at $143.0 million (Q1 2026), $141.8 million (Q4 2025), and $136.4 million (Q3 2025).